Proactive Investors - Run By Investors For Investors

Ventripoint Diagnostics increases placing to $1.5M due to demand

The proceeds will be used for sales and marketing, development and general working capital
Pictured is Canadian currency
The company has closed the order book on the offering and intends to complete the offering of debenture units at $1,000 per unit by January 25 this year

Ventripoint Diagnostics Ltd (CVE:VPT) (OTCMKTS:VPTDF) has increased its previously announced non-brokered private placement to $1.5 million from $1 million due to investor demand.

The proceeds will be used for sales and marketing, development and general working capital, the Toronto-based, heart-focused medtech company said in a statement.

READ: Ventripoint Diagnostics arranges C$1M private placement of debenture units

The company has closed the order book on the offering and intends to complete the offering of debenture units at $1,000 per unit by January 25 this year.

Each unit of the offering will include a principal amount of C$1,000 in convertible, unsecured debentures maturing in three years, as well as 6,000 common share purchase warrants, with each warrant exercisable for one common share at C$0.175 per share for 18 months.

The debentures will have an annual interest rate of 6.5%, and the company may pay a finder's fee of up to 7% of the gross proceeds.

Ventripoint uses an artificial intelligence (AI) method known as knowledge-based reconstruction to create applications monitoring heart disease.

Contact Giles at [email protected]

View full VPT profile View Profile

VentriPoint Diagnostics Ltd. Timeline

Related Articles

Sativa
June 07 2019
Geremy Thomas, founder and chief executive of Sativa, said the company has "delivered expeditiously on its investment promise to the market"
An illustration of Ozop's BLIF technique
March 30 2019
A key area of focus for the West Palm Beach, Florida, company is development of balloon lumbar interbody fusion (BLIF) technology
woman touching her skin
May 21 2019
Here we take a closer look at Integumen PLC (LON:SKIN), which has developed and digitised an artificial skin

© Proactive Investors 2019

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use